NDAORALTABLETPriority Review
Approved
Mar 2017
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Lamivudine and zidovudine is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors (NRTIs) used to treat HIV-1 infection. This oral tablet formulation combines two antiretroviral agents that work synergistically to suppress viral replication. The combination is indicated for HIV treatment in patients where dual NRTI therapy is appropriate.
Peak
Product is at peak commercial maturity with moderate competitive pressure (30%), suggesting stable but not expanding team opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This product currently shows zero linked job openings, indicating limited active hiring despite its peak lifecycle stage. Working on this mature antiretroviral combination offers experience in competitive HIV markets and managed-care strategies, though career growth may be constrained by market saturation and the shift toward newer treatment modalities.
Brand ManagerMedical Science Liaison
Worked on LAMIVUDINE AND ZIDOVUDINE at Aspen Pharmacare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.